Oxidative Stress and Pyroptosis in Doxorubicin-Induced Heart Failure and Atrial Fibrillation
Oxidative Medicine and Cellular Longevity · 24.01.2023 · 2023 · 1-8
DOI: 10.1155/2023/4938287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oxidative Medicine and Cellular Longevity, erschienen am 24.01.2023. Verfasst von Zhang Ping und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006 Jiangxi, C…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Heart Failure. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Patients undergoing doxorubicin (Dox) chemotherapy often develop new-onset atrial fibrillation and heart failure. Recent studies indicate that the TLR4/MyD88/NLRP3 pyroptosis signaling pathway plays a key role in the occurrence and development of cancer, heart failure, and atherosclerosis. However, few studies investigated the role of oxidative stress and pyroptosis in doxorubicin-induced heart failure and new-onset atrial fibrillation. In this study, we recruited 84 healthy subjects, 112 patients undergoing Dox chemotherapy showing heart failure (HF), and 62 patients undergoing Dox treatment who manifested atrial fibrillation (AF). The mRNA and protein levels of TLR4 expression, several downstream pyroptosis-associated proteins (cleaved caspase-1, NLRP3, GSDMD-N, and HMGB-1), serum inflammatory factors, and oxidative stress were detected at the beginning of chemotherapy and after 3 months of Dox chemotherapy. Oxidative stress and downstream pyroptosis-associated proteins tended to increase in the Dox-baseline group to the Dox-HF group. However, virtually no change in the expression of either oxidative stress or pyroptosis-associated proteins was detected in patients after three months of Dox chemotherapy compared with those at baseline. This study suggests that the prolonged oxidative stress and high levels of pyroptosis-associated proteins contribute to cardiac systolic dysfunction, suggesting TLR4 as a novel biomarker and a potential treatment target for doxorubicin-induced heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006 Jiangxi, China.
- Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006 Jiangxi, China.
- Department of Cardiology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000 Zhejiang, China.
ORCID-Profile: Shao Liang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ping, Z., Fangfang, T., Yuliang, Z., Xinyong, C., Lang, H., Fan, H., Jun, M., & Liang, S. (2023). Oxidative Stress and Pyroptosis in Doxorubicin-Induced Heart Failure and Atrial Fibrillation. Oxidative Medicine and Cellular Longevity, 2023, 1-8. https://doi.org/10.1155/2023/4938287
Vancouver
Ping Z, Fangfang T, Yuliang Z, Xinyong C, Lang H, Fan H, et al. Oxidative Stress and Pyroptosis in Doxorubicin-Induced Heart Failure and Atrial Fibrillation. Oxidative Medicine and Cellular Longevity. 2023;2023:1-8. doi:10.1155/2023/4938287
BibTeX
@article{Ping2023,
author = {Ping, Zhang and Fangfang, Tou and Yuliang, Zhan and Xinyong, Cai and Lang, Hong and Fan, Hu and Jun, Ma and Liang, Shao},
title = {Oxidative Stress and Pyroptosis in Doxorubicin-Induced Heart Failure and Atrial Fibrillation},
journal = {Oxidative Medicine and Cellular Longevity},
year = {2023},
volume = {2023},
pages = {1--8},
doi = {10.1155/2023/4938287}
}
EUVIMED